[Current status and prospects of cancer vaccine therapy]

Area of Science:

• Oncology and Immunology
• Cancer Vaccine Development

Context:

• Cancer vaccines have evolved significantly since the 1990s, with approved dendritic cell vaccines and developing peptide vaccines.
• Peptide vaccines are advantageous due to their antigen-specificity, scalability, and economic viability for global cancer treatment.
• Challenges remain, including limited clinical response and potential for adverse immune reactions.

Purpose:

• To highlight the potential of cancer peptide vaccines.
• To identify the need for biomarkers to predict clinical efficacy.
• To emphasize the necessity of methods for monitoring immune responses in large-scale clinical trials.

Summary:

• Cancer peptide vaccines, derived from tumor-associated antigens, show promise for prolonged survival in patients with cancers like melanoma and prostate cancer.
• Their high antigen-specificity and mass production capabilities make them economically viable, but challenges like immune escape and unfavorable responses persist.
• Development requires biomarkers for clinical effects and methods to assess immune responses for vaccines used alone or in combination therapies.

Impact:

• Advances in cancer vaccine research can lead to more effective and personalized cancer treatments.
• Identifying reliable biomarkers will improve patient selection and treatment monitoring for cancer immunotherapies.
• Further development of cancer peptide vaccines could expand global access to advanced cancer care.